Elevate your local knowledge

Sign up for the iNFOnews newsletter today!

Select Region

Selecting your primary region ensures you get the stories that matter to you first.

Valeant, attempting to normalize operations, names new CFO

NEW YORK – Valeant Pharmaceuticals is replacing Robert Rosiello as chief financial officer as the embattled pharmaceutical company attempts to normalize operations amid a host of ongoing investigations and class action suits.

The Canadian company named Paul Herendeen, former Zoetis chief financial officer, to fill the post immediately.

The company has been under fire for its strategy of buying smaller drug companies, then hiking the prices of the drugs that those companies make.

Earlier this year, Valeant Pharmaceuticals International Inc. ousted Michael Pearson, the CEO who engineered the company’s acquisition strategy, replacing him with Joseph Papa.

Valeant is the target of at least 11 investigations in the U.S. and Canada, and a number of class action suits.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Join the Conversation!

Want to share your thoughts, add context, or connect with others in your community?

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.